Earnings
Home›Earnings›Results›Johnson & Johnson tops Q2 estimates and lifts 2026 gui…
Johnson & Johnson tops Q2 estimates and lifts 2026 guidance
The company raised its full-year outlook to $100.8 billion to $101.4 billion in reported sales, with adjusted EPS guidance midpoint at $11.68.
Johnson & Johnson reported stronger-than-expected second-quarter results and increased its full-year 2026 guidance, citing solid pharmaceutical performance that helped offset headwinds from products facing patent competition, according to Yahoo Finance.
Adjusted earnings per share for the quarter came in at $2.90, ahead of the $2.85 consensus estimate, while revenue rose 6.6% year over year to $25.31 billion, compared with analysts' expectations of $25.05 billion. Net earnings were $5.53 billion, or $2.27 per diluted share, versus $5.54 billion, or $2.29 per share, a year earlier.
The company said its Innovative Medicine segment drove growth, with sales up 7.8% to $16.38 billion, and MedTech sales increasing 4.5% to $8.93 billion. Immunology drug Tremfya generated $2.0 billion in sales, up 72.5% year over year, and cancer therapy Darzalex contributed to growth as the company navigated patent expirations affecting older medicines such as Stelara.
For 2026, Johnson & Johnson now expects reported sales of $100.8 billion to $101.4 billion and adjusted EPS of $11.60 to $11.75, with an updated midpoint adjusted EPS of $11.68. The outlet also reported year-to-date free cash flow of approximately $8.7 billion, up from $6.21 billion in the prior-year period, and shares were little changed at $253 after the release.